Current and potential applications of host-defense peptides and proteins in urology

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Lo, Joey Chor Yee ^a   Lange, Dirk ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN DERIVATIVE; PEPTIDE; PROTEIN;

DRUG ACTIVITY; DRUG INDICATION; HUMAN; KIDNEY CANCER; MEDICAL DEVICE; NEPHROLITHIASIS; PROSTATE CANCER; REVIEW; URINARY TRACT INFECTION; UROLOGY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; IMMUNITY; MOLECULAR GENETICS;

BACTERIA (MICROORGANISMS);

AMINO ACID SEQUENCE; ANIMALS; HUMANS; IMMUNITY; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEINS; UROLOGY;

EID: 84925321765     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/189016     Document Type: Review

References (77)

1. G. F. Gibberd, " Prontosil etc. in puerperal Streptococcus infections," British Medical Journal, vol. 2, no. 4005, pp. 695-698, 1937.
2. J. Davies and D. Davies, "Origins and evolution of antibiotic resistance," Microbiology and Molecular Biology Reviews, vol. 74, no. 3, pp. 417-433, 2010.
3. B. Spellberg, R. Guidos, D. Gilbert et al., "The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America," Clinical Infectious Diseases, vol. 46, no. 2, pp. 155-164, 2008.
4. S. R. Dennison, F. Harris, M. Mura, L. H. G. Morton, A. Zvelindovsky, and D. A. Phoenix, "A novel form of bacterial resistance to the action of eukaryotic host defense peptides, the use of a lipid receptor," Biochemistry, vol. 52, no. 35, pp. 6021-6029, 2013.
5. D. A. Tadesse, S. Zhao, E. Tong et al., "Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950-2002," Emerging Infectious Diseases, vol. 18, no. 5, pp. 741-749, 2012.
6. I. M. Cullen, R. P. Manecksha, E. McCullagh et al., "The changing pattern of antimicrobial resistance within 42 033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009," BJU International, vol. 109, no. 8, pp. 1198-1206, 2012.
7. D. Minardi, R. Ghiselli, O. Cirioni et al., "The antimicrobial peptide Tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model," Peptides, vol. 28, no. 12, pp. 2293-2298, 2007.
8. R. E. Hancock, "Cationic peptides: effectors in innate immunity and novel antimicrobials," The Lancet Infectious Diseases, vol. 1, no. 3, pp. 156-164, 2001.
9. C. D. Fjell, J. A. Hiss, R. E. W. Hancock, and G. Schneider, "Designing antimicrobial peptides: form follows function," Nature Reviews Drug Discovery, vol. 11, no. 1, pp. 37-51, 2012.
10. M. L. Mangoni, "Host-defense peptides: from biology to therapeutic strategies," Cellular and Molecular Life Sciences, vol. 68, no. 13, pp. 2157-2159, 2011.
11. S. A. Baltzer and M. H. Brown, "Antimicrobial peptides-promising alternatives to conventional antibiotics," Journal of Molecular Microbiology and Biotechnology, vol. 20, no. 4, pp. 228-235, 2011.
12. R. E. Hancock and H.-G. Sahl, "Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies," Nature Biotechnology, vol. 24, no. 12, pp. 1551-1557, 2006.
13. R. L. Williams, H. Y. Sroussi, K. Leung, and P. T. Marucha, "Antimicrobial decapeptide KSL-W enhances neutrophil chemotaxis and function," Peptides, vol. 33, no. 1, pp. 1-8, 2012.
14. A. S. Ali, C. L. Townes, J. Hall, and R. S. Pickard, "Maintaining a sterile urinary tract: the role of antimicrobial peptides," The Journal of Urology, vol. 182, no. 1, pp. 21-28, 2009.
15. A. K. Marr, W. J. Gooderham, and R. E. Hancock, "Antibacterial peptides for therapeutic use: obstacles and realistic outlook," Current Opinion in Pharmacology, vol. 6, no. 5, pp. 468-472, 2006.
16. K. A. Brogden, "Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?" Nature Reviews Microbiology, vol. 3, no. 3, pp. 238-250, 2005.
17. L. A. Haversen, I. Engberg, L. Baltzer, G. Dolphin, L. A. Hanson, and I. Mattsby-Baltzer, "Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice," Infection and Immunity, vol. 68, no. 10, pp. 5816-5823, 2000.
18. G. Gao, D. Lange, K. Hilpert et al., "The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides," Biomaterials, vol. 32, no. 16, pp. 3899-3909, 2011.
19. X. Li, P. Li, R. Saravanan et al., "Antimicrobial functionalization of silicone surfaces with engineered short peptides having broad spectrum antimicrobial and salt-resistant properties," Acta Biomaterialia, vol. 10, no. 1, pp. 258-266, 2014.
20. J. Lehmann, M. Retz, S. S. Sidhu et al., "Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines," European Urology, vol. 50, no. 1, pp. 141-147, 2006.
21. M. A. Baker, W. L. Maloy, M. Zasloff, and L. S. Jacob, "Anticancer efficacy of Magainin2 and analogue peptides," Cancer Research, vol. 53, no. 13, pp. 3052-3057, 1993.
22. P. W. Soballe, W. L. Maloy, M. L. Myrga, L. S. Jacob, and M. Herlyn, "Experimental local therapy of human-melanoma with lytic magainin peptides," International Journal of Cancer, vol. 60, no. 2, pp. 280-284, 1995.
23. H. Suttmann, M. Retz, F. Paulsen et al., "Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells," BMC Urology, vol. 8, article 5, 2008.
24. W. Huang, J. Seo, S. B. Willingham et al., "Learning from hostdefense peptides: cationic, amphipathic peptoids with potent anticancer activity," PLoS ONE, vol. 9, no. 2, Article ID e90397, 2014.
25. C. D. Donald, C. Q. Sun, S. D. Lim et al., "Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas," Laboratory Investigation, vol. 83, no. 4, pp. 501-505, 2003.
26. C. Q. Sun, R. Arnold, C. Fernandez-Golarz et al., "Human β-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma," Cancer Research, vol. 66, no. 17, pp. 8542-8549, 2006.
27. R. S. Bullard, W. Gibson, S. K. Bose et al., "Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer," Molecular Immunology, vol. 45, no. 3, pp. 839-848, 2008.
28. S. Farmanesh, J. Chung, D. Chandra, R.D. Sosa, P. Karande, and J. D. Rimer, "High-throughput platform for design and screening of peptides as inhibitors of calcium oxalate monohydrate crystallization," Journal of Crystal Growth, vol. 373, pp. 13-19, 2013.
29. M. Chromek, Z. Slamová, P. Bergman et al., "The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection," Nature Medicine, vol. 12, no. 6, pp. 636-641, 2006.
30. J. D. Spencer, A. L. Schwaderer, H. Wang et al., "Ribonuclease 7, an antimicrobial peptide upregulated during infection, contributes to microbial defense of the human urinary tract," Kidney International, vol. 83, no. 4, pp. 615-625, 2013.
31. T. Weichhart, M. Haidinger, W. H. Hörl, and M. D. Säemann, "Current concepts of molecular defence mechanisms operative during urinary tract infection," European Journal of Clinical Investigation, vol. 38, supplement 2, pp. 29-38, 2008.
32. E.V. Valore, C. H. Park, A. J. Quayle, K. R. Wiles, P. B. McCray Jr., and T. Ganz, "Human β-defensin-1: an antimicrobial peptide of urogenital tissues," The Journal of Clinical Investigation, vol. 101, no. 8, pp. 1633-1642, 1998.
33. Y. Pan, G. A. Sonn, M. L. Y. Sin et al., "Electrochemical immunosensor detection of urinary lactoferrin in clinical samples for urinary tract infection diagnosis," Biosensors and Bioelectronics, vol. 26, no. 2, pp. 649-654, 2010.
34. D. Legrand, E. Elass, A. Pierce, and J. Mazurier, "Lactoferrin and host defence: an overview of its immuno-modulating and antiinflammatory properties," BioMetals, vol. 17, no. 3, pp. 225-229, 2004.
35. B. Rivas-Santiago, C. J. Serrano, and J. A. Enciso-Moreno, "Susceptibility to infectious diseases based on antimicrobial peptide production," Infection and Immunity, vol. 77, no. 11, pp. 4690-4695, 2009.
36. K. L. Nielsen, P. Dynesen, P. Larsen, L. Jakobsen, P. S. Andersen, and N. Frimodt-Møller, "Role of urinary cathelicidin LL-37 and human β-defensin 1 in uncomplicated escherichia coli urinary tract infections," Infection and Immunity, vol. 82, no. 4, pp. 1572-1578, 2014.
37. O. Hertting, Å. Holm, P. Lüthje et al., "Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder," PLoS ONE, vol. 5, no. 12, Article IDe15580, 2010.
38. C. E. Rivas-Santiago, B. Rivas-Santiago, D. A. León, J. Castañeda-Delgado, and R. Hernández Pando, "Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis," Clinical and Experimental Immunology, vol. 164, no. 1, pp. 80-89, 2011.
39. M. Schwab, V. Reynders, Y. Shastri, S. Loitsch, J. Stein, and O. Schröder, "Role of nuclear hormone receptors in butyratemediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells," Molecular immunology, vol. 44, no. 8, pp. 2107-2114, 2007.
40. J. Schauber, R. A. Dorschner, A. B. Coda et al., "Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism," The Journal of Clinical Investigation, vol. 117, no. 3, pp. 803-811, 2007.
41. P. Lüthje, A. Lindén Hirschberg, and A. Brauner, "Estrogenic action on innate defense mechanisms in the urinary tract," Maturitas, vol. 77, no. 1, pp. 32-36, 2014.
42. B. Becknell, J. D. Spencer, A. R. Carpenter et al., "Expressionand antimicrobial function of beta-defensin 1 in the lower urinary tract," PLoS ONE, vol. 8, no. 10, Article IDe77714, 2013.
43. J. Lo, D. Lange, and B. Chew, "Ureteral stents and foley catheters-associated urinary tract infections: the role of coatings and materials in infection prevention," Antibiotics, vol. 3, no. 1, pp. 87-97, 2014.
44. P. J. Nowatzki, R. R. Koepsel, P. Stoodley et al., "Salicylic acid-releasing polyurethane acrylate polymers as anti-biofilm urological catheter coatings," Acta Biomaterialia, vol. 8, no. 5, pp. 1869-1880, 2012.
45. F. L. Brancatisano, G. Maisetta, M. Di Luca et al., "Inhibitory effect of the human liver-derived antimicrobial peptide hepcidin 20 on biofilms of polysaccharide intercellular adhesin (PIA)-positive and PIA-negative strains of Staphylococcus epidermidis," Biofouling, vol. 30, no. 4, pp. 435-446, 2014.
46. J. W. Costerton, P. S. Stewart, and E. P. Greenberg, "Bacterial biofilms: a common cause of persistent infections," Science, vol. 284, no. 5418, pp. 1318-1322, 1999.
47. N. Høiby, T. Bjarnsholt, M. Givskov, S. Molin, and O. Ciofu, "Antibiotic resistance of bacterial biofilms," International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 322-332, 2010.
48. N. Hoiby, O. Ciofu, H. K. Johansen et al., "The clinical impact of bacterial biofilms," International Journal of Oral Science, vol. 3, no. 2, pp. 55-65, 2011.
49. "Cancer research UK," Nature Cell Biology, vol. 4, no. 3, article E45, 2002.
50. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
51. W. Oosterlinck, B. Lobel, G. Jakse, P.-U. Malmström, M. Stöckle, and C. Sternberg, "Guidelines on bladder cancer," European Urology, vol. 41, no. 2, pp. 105-112, 2002.
52. A. Stenzl, N. C. Cowan, M. de Santis et al., "Treatment of muscle-invasive and metastatic bladder cancer: update of the EAUguidelines," European Urology, vol. 59, no. 6, pp. 1009-1018, 2011.
53. A. Böhle, D. Jocham, and P. R. Bock, "Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity," The Journal of Urology, vol. 169, no. 1, pp. 90-95, 2003.
54. M. Brausi, J. Oddens, R. Sylvester et al., "Side effects of bacillus calmette-guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG," European Urology, vol. 65, no. 1, pp. 69-76, 2014.
55. A. P. M. van der Meijden, M. Brausi, V. Zambon et al., "Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk TA, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial," The Journal of Urology, vol. 166, no. 2, pp. 476-481, 2001.
56. J. I. Fletcher, M. Haber, M. J. Henderson, and M. D. Norris, "ABC transporters in cancer:more than just drug efflux pumps," Nature Reviews Cancer, vol. 10, no. 2, pp. 147-156, 2010.
57. R. A. Cruciani, J. L. Barker, M. Zasloff, H.-C. Chen, and O. Colamonici, "Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3792-3796, 1991.
58. Y. Ohsaki, A. F. Gazdar, H.-C. Chen, and B. E. Johnson, "Antitumor activity of magainin analogues against human lung cancer cell lines," Cancer Research, vol. 52, no. 13, pp. 3534-3538, 1992.
59. W. L. Maloy and U. P. Kari, "Structure-activity studies on magainins and other host defense peptides," Biopolymers, vol. 37, no. 2, pp. 105-122, 1995.
60. R. Bessalle, A. Kapitkovsky, A. Gorea, I. Shalit, and M. Fridkin, "All-D-magainin: chirality, antimicrobial activity and proteolytic resistance," FEBS Letters, vol. 274, no. 1-2, pp. 151-155, 1990.
61. R. J. Boohaker, M. W. Lee, P. Vishnubhotla, J.M. Perez, and A. R. Khaled, "The use of therapeutic peptides to target and to kill cancer cells," Current Medicinal Chemistry, vol. 19, no. 22, pp. 3794-3804, 2012.
62. D. Winder, W. H. Günzburg, V. Erfle, and B. Salmons, "Expression of antimicrobial peptides has an antitumour effect in human cells," Biochemical and Biophysical Research Communications, vol. 242, no. 3, pp. 608-612, 1998.
63. H. G. Boman, "Antibacterial peptides: basic facts and emerging concepts," Journal of Internal Medicine, vol. 254, no. 3, pp. 197-215, 2003.
64. N. P. Chongsiriwatana, J. A. Patch, A. M. Czyzewski et al., "Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 8, pp. 2794-2799, 2008.
65. N. Droin, J.-B. Hendra, P. Ducoroy, and E. Solary, "Human defensins as cancer biomarkers and antitumour molecules," Journal of Proteomics, vol. 72, no. 6, pp. 918-927, 2009.
66. J. Tang, P. Mettler, K. Mcfann, and M. Chonchol, "The association of prevalent kidney stone disease with mortality in US adults: the national health and nutrition examination survey III, 1988-1994," American Journal of Nephrology, vol. 37, no. 5, pp. 501-506, 2013.
67. K. K. Stamatelou, M. E. Francis, C. A. Jones, L. M. Nyberg Jr., and G. C. Curhan, "Time trends in reported prevalence of kidney stones in the United States: 1976-1994," Kidney International, vol. 63, no. 5, pp. 1817-1823, 2003.
68. A. D. Rule, A. E. Krambeck, and J. C. Lieske, "Chronic kidney disease in kidney stone formers," Clinical Journal of the American Society of Nephrology, vol. 6, no. 8, pp. 2069-2075, 2011.
69. F. L. Coe and J. R. Asplin, "Stopping the stones," Science, vol. 330, no. 6002, pp. 325-326, 2010.
70. B. P. H. Chan, K. Vincent, G. A. Lajoie, H. A. Goldberg, B. Grohe, and G. K. Hunter, "On the catalysis of calcium oxalate dihydrate formation by osteopontin peptides," Colloids and Surfaces B: Biointerfaces, vol. 96, pp. 22-28, 2012.
71. J. C. Lieske and F. G. Toback, "Renal cell-urinary crystal interactions," Current Opinion in Nephrology and Hypertension, vol. 9, no. 4, pp. 349-355, 2000.
72. N. S. Mandel and G. S. Mandel, "Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition," Journal of Urology, vol. 142, no. 6, pp. 1516-1521, 1989.
73. B. B. Tomazic and G. H. Nancollas, "The kinetics of dissolution of calcium oxalate hydrates. II. The dihydrate," Investigative Urology, vol. 18, no. 2, pp. 97-101, 1980.
74. D. T. Denhardt, M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman, "Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival," The Journal of Clinical Investigation, vol. 107, no. 9, pp. 1055-1061, 2001.
75. T. Uede, Y. Katagiri, J. Iizuka, and M. Murakami, "Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein?" Microbiology and Immunology, vol. 41, no. 9, pp. 641-648, 1997.
76. K. Singh, D. Deonarine, V. Shanmugam et al., "Calciumbinding properties of osteopontin derived fromnon-osteogenic sources," Journal of Biochemistry, vol. 114, no. 5, pp. 702-707, 1993.
77. T. Jung, X. Sheng, C. K. Choi, W.-S. Kim, J.A. Wesson, and M.D. Ward, "Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy," Langmuir, vol. 20, no. 20, pp. 8587-8596, 2004.